Hangzhou Tigermed Consulting Co., Ltd. Class A · SZSE:300347
Hangzhou Tigermed Consulting Co., Ltd. Class A — H1 2025 Earnings Presentation
33 slides from Hangzhou Tigermed Consulting Co., Ltd. Class A's earnings presentation, August 2025
Slide 1: 2025 Interim Results
2025 Interim Results Hangzhou Tigermed Consulting Co., Ltd. 300347.SZ / 3347.HK August 2025
Slide 2: Disclaimer
Disclaimer This document is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2025 interim results announcement and other relevant announcements published on the websites of the Shenzhen Stock Exchange (
Slide 3: Interim Results Overview
Tigermed 01 = Oo ra a) > e) ie = i?) GW) a = © &
Slide 4: Continued Recovery in Q2 2025 Results
Continued Recovery in Q2 2025 Results Adjusted Net Profit Attributable to the Owners of Revenue Gross Profit and Margin the Company and Margin (1) (RMB mm) (RMB mm) (RMB mm) 30.0% 30.1% 6.5% 6.4% +7.8% +8.2% +6.0% 1,686.3 1,564.1 508.2 469.8 108.4 102.3 1Q2025 2Q2025 1Q2025 2Q2025 1Q2025 2Q2025 (1)
Slide 5: 2025 Interim Result Key Financials
2025 Interim Result Key Financials Adjusted Net Profit Attributable to the Owners of Revenue Gross Profit and Margin the Company and Margin (1) (RMB mm) (RMB mm) (RMB mm) 39.7% 30.1% 19.1% 6.5% -3.2% -26.6% -67.1% 3,358.2 3,250.4 1,333.0 1,721.1 640.3 1,780.9 978.0 705.0 642.8 1,637.1 210.7 1,469.5
Slide 6: Revenue Breakdown by China and Overseas Market
Revenue Breakdown by China and Overseas Market China Revenue Overseas Revenue Revenue Breakdown by Region (RMB mm) (RMB mm) 48% 52% 1H2025 -9.2% +4.4% China Overseas 1,870.4 1,697.9 1,487.8 1,552.5 44% 1H2024 56% 1H2024 1H2025 1H2024 1H2025 China Overseas 6
Slide 7: Operating Costs
Operating Costs Operating Cost Breakdown by Nature and as % of Revenue (RMB mm) 60.3% 69.9% 2,272.5 +12.2% 2,025.2 9.4% 7.3% 22.6% 19.0% 34.0% 37.9% 1H2024 1H2025 Direct labor costs Direct project-related costs Overhead costs 7
Slide 8: Operating Expenses
Operating Expenses Selling and Marketing Expenses Administrative Expenses and as R&D Expenses and as % of Share-based Compensation and as % of Revenue % of Revenue Revenue and as % Revenue (RMB mm) (RMB mm) (RMB mm) (RMB mm) 3.0% 3.3% 11.2% 10.9% 3.7% 3.9% 1.4% 0.3% +6.4% -5.7% +1.8% -78.5% 107.9 10
Slide 9: Business Updates
02 Business Updates Clinical Trial Solutions (“CTS”)
Slide 10: Clinical Trial Solutions ("CTS")
Clinical Trial Solutions (“CTS”) Segment 板块收入 Revenue Segment毛利润和毛利率 Gross Profit and Margin （百万元人民币） （百万元人民币） 38.4% 22.8% -10.2% -46.6% 1,637.1 1,469.5 628.0 335.2 1H2024 1H2025 1H2024 1H2025 10
Slide 11: CTS Key Business Updates
CTS Key Business Updates Number of Ongoing Drug Clinical Research Number of Ongoing Drug Clinical Research Projects by Phase(1) Projects by Region(1) 831 831 800 800 62 111 55 91 30 27 646 646 208 233 43 192 203 95 15 194 144 147 159 116 537 536 409 340 331 276 06/30/2024 12/31/2024 06/30/2025 (3) 0
Slide 12: Overseas Clinical Operation Business Updates
Overseas Clinical Operation Business Updates Number of Ongoing Overseas Drug Clinical Research(1) Our employees reached 10,251 globally, including more than 1,700 overseas employees in 33 countries 295 Our medical imaging and clinical service capabilities in Japan and the Asia-Pacific region are exp
Slide 13: Global Clinical Operation Business Updates (Cont'd)
Global Clinical Operation Business Updates (Cont’d) North America ⚫ As of June 30, 2025, our clinical team in the U.S. had nearly 200 people, covering 68 cities in 27 states ⚫ In H1 2025, our U.S. team contributed to the FDA approval and market launch of Felix NeuroAI Wristband, the world's first AI
Slide 14: Acquisition of Japanese CRO -- Micron
Acquisition of Japanese CRO -- Micron Micron Headquarter 3-13-16 Mita, Minato-ku, Tokyo, Japan www.microncro.com ⚫ Completed the acquisition of Micron, a Japanese CRO company, in July 2025. Imaging Service ⚫ Founded in 2005 and headquartered in Tokyo, Micron is a Japan-based Contract Research Organi
Slide 15: Industry Updates in H1 2025
Industry Updates in H1 2025 Industry Valuation Reshaped The Booming Out-licensing Deals ⚫ As of the end of June 2025, the HKEx Innovative Drug Index had surged over 60%, ⚫ In H1 2025, Chinese domestic drug manufacturers’ outbound licensing deals the Wind Innovative Drug Index had risen over25%, and
Slide 16: Chinese Innovative Drug Industry Fastly Integrated to Global Market
Chinese Innovative Drug Industry Fastly Integrated to Global Market Prices of Chinese innovative assets being significantly undervalued compared to European and American markets Dollarization of value of Chinese innovative assets China Developed- country markets RMBization of global R&D costs China’
Slide 17: CTS Key Business Updates
CTS Key Business Updates Regulatory Affairs (RA) ⚫ As of June 30, 2025, our RA team cumulatively finished 1,351 registration and submission projects ⚫ Added 29 new FDA IND projects in H1 2025, wherein, 21 had obtained clinical approvals from the FDA. ⚫ In H1 2025, our RA team facilitated 1 product i
Slide 18: CTS Key Business Updates (Cont'd)
CTS Key Business Updates (Cont’d) Pharmacovigilance (PV) ⚫ Our PV team had over 190 people globally, forming an integrated PV solution team covering the U.S., Europe, Japan, Southeast Asia and China in H1 2025. ⚫ As of June 30, 2025, our global PV client base exceeded 300 clients, and our PV team ha
Slide 19: CTS Key Business Updates (Cont'd)
CTS Key Business Updates (Cont’d) Decentralized Clinical Trials (“DCTs”) ⚫ Released the 2024 Research and Analysis Report on Industry Development Status Quo of Digital/Decentralized Clinical Trials ⚫ The mobile-end version of Tigermed's self-developed Clinical Trial Remote Monitoring (CTRM) system w
Slide 20: Business Updates
03 Business Updates Clinical-related and Lab Services (“CRLS”)
Slide 21: Clinical-related and Lab Services ("CRLS")
Clinical-related and Lab Services (“CRLS”) Segment Gross Profit and Revenue Margin (RMB mm) (RMB mm) 41.0% 36.1% +3.5% -8.8% 1,721.1 1,780.9 705.0 642.8 1H2024 1H2025 1H2024 1H2025 21
Slide 22: Clinical-related and Lab Services ("CRLS") (Cont'd)
Clinical-related and Lab Services (“CRLS”) (Cont’d) Status of partial business projects within the segment Data Management and Statistical Analysis Site Management Laboratory Services Completed Conducted 284 by team based overseas Completed 2,443 5,818 4,549 Conducted 4,667 4,544 609 by team Complet
Slide 23: Clinical-related and Lab Services ("CRLS")
Clinical-related and Lab Services (“CRLS”) Data Management and Statistical Analysis (DMSA) ⚫ As of June 30, 2025, we had cumulatively handled over 2,800 CDISC projects. ⚫ In H1 2025, we provided support to multiple overseas submission standardization projects for drug data of licensed-out products o
Slide 24: Clinical-related and Lab Services ("CRLS") (Cont'd)
Clinical-related and Lab Services (“CRLS”) (Cont’d) Site Management (“SMO”) ⚫ As of June 30, 2025, the total number of our ongoing SMO projects was 2,443; and we have completed 215 SMO projects completed in H1 2025. ⚫ The number of our newly-signed SMO orders in H1 2025 grew by 12% YoY compared to H
Slide 25: Other Updates
(Dermed 04 Other Updates
Slide 26: Updates of Investment Activities
Updates of Investment Activities Realized Investment Gain and Fair Value Gain(1) (RMB mm) （百万元人民币） 24.7 ⚫ Portfolio included 195 companies in the healthcare industry and 54 investment funds of June 30, 2025 4.8 ⚫ RMB 10.25 billion balance as of June 30, 2025 1H2024 1H2025 ⚫ Invested RMB 170.3 millio
Slide 27: Employee Base
Employee Base The number of our employees slightly increased to 10,251 as of June 30, 2025 from 10,185 as of December 31,2024 Employees Mix by Function(1) Employees Mix by Geography(1) Overseas and Hong Kong China, 管理及行政 Management and administration Macao China, Taiwan China 578 564 1,709 Marketing
Slide 28: Appendix
Tigermed 05 Ras ae) c ® 2. oY <x
Slide 29: Consolidated Statement of Profit or Loss
Consolidated Statement of Profit or Loss Six months as of June 30 (RMB 000s) 2024 2025 I Total operating revenue 3,358,244 3,250,444 Including: Operating Revenue 3,358,244 3,250,444 II Total operating costs (2,626,270) (2,942,263) Including: Operating cost (2,025,197) (2,272,466) Business tax and su
Slide 30: Net profit attributable to shareholders after deducting extraordinary gain or loss
Net profit attributable to shareholders of the Company after deducting extraordinary gain or loss Six months as of June 30 (RMB 000s) 2024 2025 Net profits attributable to shareholders of the parent 492,849 383,337 Adjusted for: Loss/(gain) from disposal of non-current assets (1,490) (626) Governmen
Slide 31: Consolidated Statement of Financial Position
Consolidated Statement of Financial Position (RMB 000s) As of December 31, 2024 As of June 30, 2025 NON-CURRENT ASSETS 22,371,329 22,298,198 Long-term equity investments 3,424,603 4,078,244 Other equity instrument investments 8,090 9,497 Other non-current financial assets 10,105,905 10,150,409 Fixed
Slide 32: Consolidated Statement of Financial Position (Cont'd)
Consolidated Statement of Financial Position (Cont’d) (RMB 000s) As of December 31, 2024 As of June 30, 2025 CURRENT LIABILITIES 3,661,851 3,395,689 Short-term borrowings 1,912,017 1,439,392 Notes payables - 6,135 Accounts Payables 257,287 306,867 Contract liabilities 790,737 943,308 Employee benefi
Slide 33: Hangzhou Tigermed Consulting Co., Ltd.
Hangzhou Tigermed Consulting Co., Ltd. 300347.SZ / 3347.HK August 2025
Hangzhou Tigermed Consulting — H1 2025 Earnings Presentation on 6ix